Credit Suisse’s ARK Genomic Revolution ETF ARKG Stock Holding History

Credit Suisse’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$3.47M	Sell	120,757 -17,087	-12%	-$514K	﹤0.01%	1511
2023 Q4	$4.52M	Buy	137,844 +64,286	+87%	+$1.75M	﹤0.01%	1396
2023 Q3	$2.05M	Buy	73,558 +28,580	+64%	+$934K	﹤0.01%	1823
2023 Q2	$1.53M	Sell	44,978 -15,325	-25%	-$482K	﹤0.01%	2104
2023 Q1	$1.81M	Buy	60,303 +18,017	+43%	+$558K	﹤0.01%	1943
2022 Q4	$1.19M	Sell	42,286 -20,578	-33%	-$653K	﹤0.01%	2226
2022 Q3	$2.07M	Sell	62,864 -35,346	-36%	-$1.3M	﹤0.01%	1831
2022 Q2	$3.09M	Sell	98,210 -89,226	-48%	-$3.12M	﹤0.01%	1615
2022 Q1	$8.61M	Sell	187,436 -96,585	-34%	-$4.6M	0.01%	1116
2021 Q4	$17.4M	Buy	284,021 +172,380	+154%	+$11.9M	0.01%	1160
2021 Q3	$8.34M	Buy	111,641 +32,301	+41%	+$2.71M	﹤0.01%	1665
2021 Q2	$7.34M	Sell	79,340 -17,420	-18%	-$1.48M	﹤0.01%	1772
2021 Q1	$8.59M	Buy	96,760 +83,760	+644%	+$8.31M	﹤0.01%	1685
2020 Q4	$1.21M	Buy	13,000 +2,500	+24%	+$199K	﹤0.01%	3189
2020 Q3	$669K	Hold	10,500	–	–	﹤0.01%	3209
2020 Q2	$548K	Buy	+10,500	New	+$450K	﹤0.01%	3267

Other funds holding ARKG

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Credit Suisse's ARKG Position: Q1 2024 in Review

Credit Suisse reduced its ARK Genomic Revolution ETF (ARKG) stake by 12% in Q1 2024, selling an estimated $514K and leaving 120,757 shares worth $3.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1511.

Credit Suisse first reported a position in ARKG in Q2 2020 and has held it in 16 quarters since. The position peaked at $17.4M in Q4 2021. 284 funds tracked by Wall St. Rank hold ARKG as of Q1 2024.

Credit Suisse held 120,757 shares of ARK Genomic Revolution ETF worth $3.47M as of Q1 2024.
Credit Suisse sold 17,087 ARK Genomic Revolution ETF shares in Q1 2024, an estimated $514K.
ARK Genomic Revolution ETF made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1511 holding.
Credit Suisse first reported a position in ARK Genomic Revolution ETF in Q2 2020 and has held it in 16 quarters since.
Credit Suisse's ARK Genomic Revolution ETF position peaked at $17.4M in Q4 2021.
284 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.